Urologic Research Studies and Clinical Trials
Research Studies by Disease Type
Researchers at the Johns Hopkins Brady Urological Institute are conducting several research studies, including clinical trials, that are looking for participants.
If you are interested in participating in a study, please reach out to Rana Harb, Senior Clinical Research Program Manager for the Brady Urological Institute, at 410-502-5500 or by emailing rharb1@jhmi.edu
If you are interested in participating in a study, please reach out to Rana Harb, Senior Clinical Research Program Manager for the Brady Urological Institute, at 410-502-5500 or by emailing rharb1@jhmi.edu
-
- A Phase 3, Randomized Study of CG0070 versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT). More information is available at NCT06111235
- The CARE trial: Comparison of Apixaban versus Enoxaparin for VTE Prevention after Radical Cystectomy (the CARE trial). This research is being done to better understand the experience of taking blood thinning medications at home after bladder removal surgery.
- A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Nave or Received Incomplete BCG Treatment. More information is available at NCT04752722
- A prospective, randomized controlled study to evaluate minimal residual disease (MRD) and long-term outcomes after transurethral resection of bladder tumor (TURBT), using blue light cystoscopy (BLC) compared to white light cystoscopy (WLC). This research is being done to evaluate the genomic burden of residual cancer in NMIBC patients who have a transurethral resection of their tumors under blue light vs white light cystoscopy.
- A retrospective study to evaluate a Valar Biomarker performance in patients with Non Muscle Invasive bladder cancer treated with Gemcitabine and docetaxel (VALAR Labs). This research is being done to evaluate the genomic burden of residual cancer in NMIBC patients who have a transurethral resection of their tumors under blue light vs white light cystoscopy.
- A prospective, randomized trial comparing prostate capsule-sparing and nerve-sparing radical cystectomy in patients with bladder cancer. This research is being done to determine if prostate capsule-sparing cystectomy improves functional outcomes, such as erectile function and maintaining urinary continence, without compromising the oncologic outcomes, or our ability to cure cancer, in patients undergoing cystectomy for bladder cancer.
- Surgical drain fluid for detection of molecular residual disease (MRD) in patients with bladder, renal and urothelial cancers. This research is being done to investigate if fragments of DNA from cancer cells can be detected in postoperative blood, tumor tissue, and surgical drain fluid and whether finding these fragments of DNA match what is seen by standard procedures such as clinical examinations, imaging studies, or future biopsies at 12- and 24- months post-surgery in patients with bladder and upper tract urothelial cancer.
-
- Automated Intraoperative Monitoring to Improve Functional Outcomes following Radical Prostatectomy-Perseus System. This research is being done to develop an automated method to monitor neurovascular structures (nerves and blood vessels) at surgical risk during Radical Prostatectomies (RP). To do this, we are developing software for an automatic monitoring program that will continuously obtain information during Radical Prostatectomies (RP). Currently there is no continuous monitoring platform available for use like the one being used in this research study.
- Comphya (Safety and tolerability of a novel implantable neurostimulator for the treatment of erectile dysfunction following radical prostatectomy). The gold standard for the treatment of prostate cancer is radical prostatectomy surgery (removal of the entire prostate). During this procedure, the nerves surrounding the prostate are often damaged. These nerves are involved in the penile erection mechanism. Therefore, erections are impaired after the surgery and 70-90% of patients will suffer from erectile dysfunction. This research is being performed to assess the safety and the tolerability of the study device, called CaverSTIM. The CaverSTIM system is intended to be implanted in the pelvic area during the prostatectomy surgery. It delivers electrical stimulation to the nerves, to trigger penile erection, help with penile recovery and promote nerve regeneration. This study is being done to assess the safety and tolerability of the CaverSTIM system for long-term implantation and use. The study will also allow us to gain initial insights on device effectiveness and patient’s satisfaction.
-
- DISSRM Registry-Delayed intervention and surveillance for small Renal masses. This is a registry study for patients on active surveillance for small renal masses that are less than 4 cm.
- The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy (#HOPE4KIDNEY US). More information is available at NCT05820087
-
- IRB00303628. Clinical Trial of Approaches to Prostate Cancer Surgery. This is a randomized trial between pelvic fascia sparing radical prostatectomy and standard prostatectomy for patient scheduled to undergo a radical prostatectomy for prostate cancer. Doctors know a lot about the performing prostate surgeries. However, we are always trying to learn more and improve our skills for our patients’ benefit. We want to try and make prostate surgeries safer, with fewer side effects for the patient, and look for a better way to remove cancer. In this study, we will monitor if there are problems after a participant’s surgery. We will also document the results of the surgery and patient-reported quality of life by collecting questionnaires.
- IRB00238159. Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complications-Cornell. This is a randomized trial of transperineal vs transrectal prostate biopsy for patients who had an elevated PSA and a prostate biopsy and are scheduled for a confirmatory prostate biopsy. This research study is being done because there are currently no good studies comparing the two types of biopsies. We want to know if one type of biopsy is better than the other for avoiding the risk of infection and for finding cancer.
- IRB00068488. Transrectal Ultrasound Robot-Assisted Prostate Biopsy. This is a randomized trial of Uronav prostate biopsy Vs Robotic prostate biopsy for patient with elevated PSA and scheduled to undergo a prostate biopsy.
- IRB00310121. Clinical Utility of Prostate Cancer Genetic Risk Assessment with the Genetic Risk Score in African American Men with Elevated Prostate Specific Antigen. We are collecting a blood sample as part of this study to look Prostate Cancer Genetic Risk Assessment with the Genetic Risk Score in African American Men with elevated PSA.
- IRB00390244. Exosome study Evaluation of ExoDx Prostate in Men with Prostate Cancer in an Active Surveillance Regimen- A Prospective Trial. More information is available at NCT05572099
- IRB00420405. Identification of urine enriched and prostate cancer-specific circulating RNAs and metabolites. As part this study, we collect a urine sample from patients to study specific circulating RNAs and metabolites.
- IRB00464204. NCI early detection research network (EDRN) prostate MRI biomarker study and reference set (PMRI). More information is available at NCT03784924
- IRB00397228. VAPOR-2-Francis Medical: Prospective, Multicenter, Single-Arm Study of Vanquish Water Vapor Ablation for PrOstate CanceR. More information is available at NCT05683691
- IRB00410442. A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer. More information is available at NCT06074510
- IRB0043359. Evaluation of oncological, functional and safety outcomes following focal cryotherapy and HIFU for the primary treatment of prostate cancer and comparison against radical prostatectomy outcomes. This is a registry study where we collect questionnaire from patients after they undergo focal therapy for prostate cancer to compare patients outcome to those undergoing an RP.
- IRB00495379. A Pivotal Study of Voro Urologic Scaffold for the Treatment of Post Prostatectomy Stress Urinary Incontinence (ARID II). More information is available at NCT06873581
- IRB00356737. Real-Time Localization of Erectogenic Nerves Using Near-Infrared Fluorophores to Guide Robotic-Assisted Radical Prostatectomy. This study is for patients diagnosed with prostate cancer, and based on physician counseling and shared decision making they have decided to undergo a radical prostatectomy as part of the standard clinical care. We hope to develop and optimize a clinically translatable strategy to identify the nerves responsible for erections during robotic prostatectomy. We hope this will minimize the rates of postoperative erectile dysfunction and thereby improve the quality of life for men with prostate cancer treated surgically in the future. Participation involves allowing us to apply an investigational compound agent to your prostate after it has been surgically removed and is outside the body.
- IRB00415995. Pilot testing of a novel sampling approach for prostate cancer detection and molecular characterization. This research is being done to test a method to detect aggressive prostate cancer using semen specimens. If the method works, the test will be relatively noninvasive and will benefit many patients in the future by sparing them the invasive procedures in the traditional biopsy pathway toward prostate cancer diagnosis.
-
- MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial-ClinicalTrials.gov Identifier. More information is available at NCT06060873
-
- Prospective Comparison of the Effect of Virtual Reality Glasses on Pain and Vital findings during Transperineal Prostate Biopsy. This research is being done to test a method to detect aggressive prostate cancer using semen specimens. If the method works, the test will be relatively noninvasive and will benefit many patients in the future by sparing them the invasive procedures in the traditional biopsy pathway toward prostate cancer diagnosis.
Clinical Trials at Johns Hopkins
Johns Hopkins Medicine is home to more than 1,000 ongoing clinical trials for a variety of conditions. Our easy-to-use clinical trials website offers many ways to search for studies recruiting participants, including healthy volunteers.